This article is more than 5 years old. Information may no longer be current.

Alimera reports second-quarter net loss of $16.4 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences generated $179,000 in the second quarter related to the launch of Iluvien in Germany and the United Kingdom, resulting in a net loss of $16.36 million for the period, according to a news release.

The company generated a net loss of $4.7 million in the second quarter of 2012 on no revenues.

Alimera’s operating expenses more than doubled from the period ended June 30, 2012, to the period ended June 30, 2013, rising to $9.5 million from $4.5 million. The increase was largely related to services, expansion and establishment of infrastructure in Europe due to the continuing launch of Iluvien (sustained-release fluocinolone acetonide).

For the first 6 months of 2013, Alimera reported a net loss of $30.35 million, up from a net loss of $9.06 million in the first half of 2012.

The company expects to launch Iluvien in France in the first quarter of 2014 while seeking increased reimbursements in Germany and the United Kingdom, according to the release.